Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Treasury
Common stock, beginning balance (in shares) at Dec. 31, 2020		69,293,920
Beginning balance at Dec. 31, 2020	$ 399,500	$ 69	$ 2,242,801	$ 105	$ (1,843,475)	$ 0
Treasury stock, beginning balance (in shares) at Dec. 31, 2020						0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Unrealized gain (loss) on available-for-sale securities	(1,303)			(1,303)
Net (loss) income	1,604,715				1,604,715
Stock-based compensation expense	53,508		53,508
Common stock issued under stock incentive plan and ESPP (in shares)		1,256,711
Common stock issued under stock incentive plan and ESPP	37,296	$ 2	37,294
Repurchase of common stock (in shares)						(16,216,411)
Repurchase of common stock	(802,486)					$ (802,486)
Disposition of oncology business	745		745
Common stock, ending balance (in shares) at Dec. 31, 2021		70,550,631
Ending balance at Dec. 31, 2021	1,291,975	$ 71	2,334,348	(1,198)	(238,760)	$ (802,486)
Treasury stock, ending balance (in shares) at Dec. 31, 2021						(16,216,411)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Unrealized gain (loss) on available-for-sale securities	(11,337)			(11,337)
Net (loss) income	(231,801)				(231,801)
Stock-based compensation expense	49,296		49,296
Common stock issued under stock incentive plan and ESPP (in shares)		705,487
Common stock issued under stock incentive plan and ESPP	$ 2,681		2,681
Common stock, ending balance (in shares) at Dec. 31, 2022	55,039,707	71,256,118
Ending balance at Dec. 31, 2022	$ 1,100,814	$ 71	2,386,325	(12,535)	(470,561)	$ (802,486)
Treasury stock, ending balance (in shares) at Dec. 31, 2022	(16,216,411)					(16,216,411)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Unrealized gain (loss) on available-for-sale securities	$ 12,094			12,094
Net (loss) income	(352,088)				(352,088)
Stock-based compensation expense	$ 44,766		44,766
Common stock issued under stock incentive plan and ESPP (in shares)	235,401	905,371
Common stock issued under stock incentive plan and ESPP	$ 5,433	$ 1	5,432
Common stock, ending balance (in shares) at Dec. 31, 2023	55,945,078	72,161,489
Ending balance at Dec. 31, 2023	$ 811,019	$ 72	$ 2,436,523	$ (441)	$ (822,649)	$ (802,486)
Treasury stock, ending balance (in shares) at Dec. 31, 2023	(16,216,411)					(16,216,411)